| Active substance | pirtobrutinib |
| Holder | S.A. Eli Lilly N.V |
| Status | Running |
| Indication | Pirtobrutinib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have been exposed to a Bruton’s tyrosine kinase (BTK) inhibitor and venetoclax (i.e. double-exposed patients). |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 23/04/2025 |